Scientists at the University of North Carolina Lineberger Comprehensive Cancer Center have identified an unexpected role for the innate immune protein cGAS, showing that it helps regulate cholesterol inside cells and may influence tumor growth and treatment response. The findings, published on November 2, 2026, in the Journal of Clinical Investigation, point to a new biological pathway that could open the door to future cancer therapies.
The protein is best known for sensing harmful DNA in the cell’s cytoplasm and triggering an immune response. But the new research suggests cGAS also works inside the nucleus, where it can bind to specific regions of the genome and help control which genes are switched on or off. The study found that cGAS increases production of LGALS3, a protein involved in regulating cholesterol levels and cell behavior.
How cGAS affects tumor growth
According to the researchers, this chain reaction reduces the cell’s production of acetyl-CoA, a molecule needed to make cholesterol. When cGAS is missing, cells accumulate excess cholesterol instead. That shift changes membrane composition and activates a growth-promoting pathway that can increase cell size, fuel tumor growth and make cancer cells more resistant to treatment.
In laboratory experiments and mouse tumor models, tumors without cGAS grew significantly faster and showed stronger activation of a key regulatory pathway. Restoring cGAS, or restoring LGALS3 alone, slowed tumor growth and reduced cholesterol buildup.
Potential relevance for treatment resistance
The study also found that cGAS-deficient cancer cells were more resistant to common chemotherapy drugs such as doxorubicin, as well as cholesterol-lowering agents. Reintroducing cGAS or LGALS3 reversed that resistance, suggesting the pathway may have broader implications for how some tumors respond to therapy.
As the researchers noted, the findings do not yet prove that cGAS affects every chemotherapy or targeted treatment in the same way. But they do suggest that tumors relying on cholesterol for survival could be especially affected by this signaling route.
The discovery may also have implications beyond cancer, since cholesterol metabolism is central to many diseases. For now, the study points to a new line of investigation into whether drugs that modulate cGAS activity, or target the LGALS3 pathway, could help slow tumor growth or improve responses to existing treatments. Source Journal Reference
Researchers say the next step is to understand how this regulatory role changes during different stages of tumor development and in the emergence of treatment resistance. If those questions can be answered, the pathway could become a promising target for future pre-clinical testing.
Photo source: AI-generated or edited image
